Publications

van der Mijn JC, Fu L, Khani F, Zhang T, Molina AM, Barbieri CE, Chen Q, Gross SS, Gudas LJ, Nanus DM.  2020.  Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma.. Transl Oncol. 13(2):177-185.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, Oromendia C, Gudas LJ, Tagawa ST, Nanus DM et al..  2022.  The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy.. Mol Oncol.

Molina AM, van der Mijn JC, Christos P, Wright J, Thomas C, Dutcher JP, Nanus DM, Tagawa ST, Gudas LJ.  2020.  NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.. Invest New Drugs.

Kubala JM, Laursen KB, Schreiner R, Williams RM, van der Mijn JC, Crowley MJ, Mongan NP, Nanus DM, Heller DA, Gudas LJ.  2023.  NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma.. Cancer Biol Ther. 24(1):2170669.

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, Chen Q, Gross SS, Nanus DM, Gudas LJ.  2023.  Novel genetically engineered mouse models for clear cell renal cell carcinoma.. Sci Rep. 13(1):8246.

van der Mijn JC, Chen Q, Laursen KB, Khani F, Wang X, Dorsaint P, Sboner A, Gross SS, Nanus DM, Gudas LJ.  2022.  Transcriptional and metabolic remodeling in clear cell renal cell carcinoma caused by ATF4 activation and the integrated stress response (ISR).. Mol Carcinog.

van der Mijn JC, Awamlh BAl Hussein, Khan AIslam, Posada-Calderon L, Oromendia C, Fainberg J, Alshak M, Elahjji R, Pierce H, Taylor B et al..  2019.  Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.. PLoS One. 14(12):e0226285.